- Details
- Description
Packaging Size:
28 tablets (1 × 28)
Strength:
200 mg
Composition:
Capmatinib hydrochloride equivalent to Capmatinib 200 mg per film-coated tablet.
Treatment:
Oral targeted anticancer medicine used for adults with metastatic non-small-cell lung cancer (NSCLC) whose tumors have a mutation resulting in MET exon 14 skipping.
Form:
Film-coated tablet
Brand:
Capmaxen 200 mg
Quantity Unit:
Tablet
Manufacturer:
Everest Pharmaceuticals Ltd., Bangladesh
Capmaxen 200 mg is an oral targeted anticancer medicine manufactured by Everest Pharmaceuticals Ltd., Bangladesh. Each film-coated tablet contains Capmatinib 200 mg, a selective MET tyrosine kinase inhibitor. It is used for the treatment of adults with metastatic non-small-cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping. Capmatinib works by blocking abnormal MET signaling, which can help slow the growth and spread of cancer cells. The recommended adult dose is 400 mg twice daily, meaning two 200 mg tablets per dose, when prescribed according to the approved regimen.
Related Products
